Category: 3. Business

The US-made narrowbody, already in use for more than a decade, had reshaped the airline industry by making shorter routes cheaper and more profitable to operate. By 1988, when Airbus began producing its upstart A320, Boeing had built a formidable lead by delivering some 1,500 of its cigar-shaped best-seller.

It’s taken the better part of four decades, but Airbus has finally caught up: The A320 series is poised to overtake its US competitor as the most-delivered commercial airliner in history, according to aviation consultancy Cirium. As of early August, Airbus had winnowed the gap to just 20 units, with 12,155 lifetime A320-family shipments, according to the data. That difference is likely to disappear as soon as next month.

“Did anyone back then expect it could become number one – and on such high production volumes?” Max Kingsley-Jones, head of advisory at Cirium Ascend, wrote of the A320 in a recent social-media post. “I certainly didn’t, and nor probably did Airbus.” 

The A320’s success mirrors the European planemaker’s decades-long rise from fledgling planemaker to serious contender, and finally Boeing’s better. By the early 2000s, annual deliveries of the A320 and its derivatives had surpassed the 737 family; total orders eclipsed the Boeing jet in 2019. But the 737 stubbornly remained the most-delivered commercial aircraft of all time. 

At the outset, Airbus faced an uphill battle. The European planemaker, an assemblage of aerospace manufacturers formed in 1970 with backing from European governments, didn’t yet offer a full aircraft lineup. Infighting hindered everything from product planning to manufacturing, and leadership decisions had to finely balance French and German commercial and political interests. 

Yet it was clear even then that Airbus needed a presence in the narrowbody segment to firmly establish itself as Boeing’s top rival. Those aircraft are by far the most widely flown category in commercial aviation, typically connecting city pairs on shorter routes. 

Higher fuel costs and the deregulation of the US aviation industry in the late 1970s had given the European planemaker an opening with American airline executives, who clamored for an all-new single-aisle, according to a history of Airbus written by journalist Nicola Clark.

To set the A320 apart, Airbus took some risks. It selected digital fly-by-wire controls that saved weight over traditional hydraulic systems, and gave pilots a side-stick at their right or left hand instead of a centrally mounted yoke. The aircraft also sat higher off the ground than the 737 and came with a choice of two engines, giving customers greater flexibility. 

Airbus’s gamble paid off. Today, the A320 and 737 make up nearly half of the global passenger jet fleet in service. And the A320’s success contrasts with strategic blunders like the A380 behemoth that proved short-lived because airlines couldn’t profitably operate the giant plane. Boeing maintained that smaller, nimbler planes like the 787 Dreamliner would have an edge — a prediction that proved right.

Read More: Boeing’s Struggles Give Airbus a Chance at Aviation Dominance

Yet the longtime dominance of the two narrowbody aircraft raises questions about the vitality of a duopoly system that favors stability over innovation. Both airplane makers have repeatedly opted for incremental changes that squeeze efficiencies out of their top-selling models, rather than going the more expensive route of designing a replacement aircraft from scratch. 

Airbus was first to introduce new engines to its A320, turning the neo variant into a huge hit with airlines seeking to cut their fuel bill. Under pressure, Boeing followed, but its approach proved calamitous. The US planemaker came up with the 737 Max, strapping more powerful engines onto the aircraft’s aging, low-slung frame. 

It installed an automated flight-stabilizing feature called MCAS to help manage the higher thrust and balance out the plane. Regulators later found MCAS contributed to two deadly 737 Max crashes that led to a global grounding of the jet for 20 months, starting in 2019.

More recently, Airbus has been bedeviled by issues with the fuel-efficient engines that power the A320neo. High-tech coatings that allow its Pratt & Whitney geared turbofans to run at hotter temperatures have shown flaws, forcing airline customers to send aircraft in for extra maintenance, backing up repair shops and grounding hundreds of jets waiting for inspection and repair. 

Read More: Lost Decade of Planemaking Costs Airlines Thousands of Jets

With both narrowbody families near the end of their evolutionary timeline, analysts and investors have begun asking about what’s next. China, for its part, is seeking to muscle into the market with its Comac C919 model that’s begun operating in the country, but hasn’t so far been certified to fly in Europe or the US. 

Boeing Chief Executive Officer Kelly Ortberg said in July that the company is working internally toward a next-generation plane, but is waiting for engine technology and other factors to fall into place, including restoring cash flow after years of setbacks. 

“That’s not today and probably not tomorrow,” he said on a July 29 call. 

Airbus’s healthier finances give it more flexibility to explore design leaps. CEO Guillaume Faury toyed with rolling out a hydrogen-powered aircraft — potentially with a radical “flying wing” design — in the mid-2030s but has since pushed back the effort to focus on a conventional A320 successor.

The Toulouse, France-based company is considering an open-rotor engine that would save fuel through its architecture rather than the current jet turbines that push the limits of physics to eke out gains.

Speaking at the Paris Air Show in June, Faury called the A320 “quite an old platform” and affirmed plans to launch a successor by the end of this decade, with service entry in the mid-2030s.

“I have a lot of focus on preparing that next-generation of single aisle,” Faury said. “We are very steady and very committed to this.”

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Binod Dhakal, MD, MS, an associate professor of medicine at the Medical College of Wisconsin, and Leonid Shunyakov, MD, an oncologist/hematologist at Citizens Memorial Hospital, discussed the application of talquetamab-tgvs (Talvey) in relapsed/refractory multiple myeloma. The discussion, part of a Between the Lines^® program hosted by CancerNetwork^®, centered on updated results from the phase 1/2 MonumenTAL-1 trial (NCT03399799; NCT04634552) shared at the meeting.¹

Talquetamab has a unique place in the treatment paradigm for multiple myeloma as it is the only approved bispecific antibody targeting GPRC5D for relapsed/refractory multiple myeloma. Regarding this mechanism of action, Dhakal said, “The exact function and mechanism of this target is not understood; however, we know it is expressed heavily on the malignant plasma cells, much more than the normal plasma cells.”

Updated Efficacy

With an extended median follow-up ranging from 30 to 38 months, the trial’s results continued to demonstrate consistent or improved efficacy and safety outcomes.

Patients in the trial were assigned to 1 of 3 treatment cohorts: the first (weekly dosing) enrolled patients who were naive to T-cell redirection therapy (TCR) and received 0.4 mg/kg of subcutaneous talquetamab once weekly (n = 143), the second (every 2-week dosing) enrolled patients who were TCR-naive who were administered 0.8 mg/kg of subcutaneous talquetamab once every 2 weeks (n = 154), and the third (prior TCR weekly and every 2-week dosing) enrolled patients who received prior TCR and were administered either 0.4 mg/kg once weekly or 0.8 mg/kg once every 2 weeks (n = 78).

In the first cohort, the overall response rate (ORR) was 74.1%, with a complete response (CR) or better rate of 32.9%, a very good partial response (VGPR) rate of 26.6%, and a PR rate of 14.7%. In the second cohort, the ORR was 69.5%, with a CR or better rate of 40.3%, a VGPR rate of 18.8%, and a PR rate of 10.4%. In the third cohort, the ORR was 66.7%, with a CR or better rate of 42.3%, a VGPR rate of 12.8%, and a PR rate of 11.5%.

Notably, however, in the first and second cohorts, the patients were naive to TCR, whereas in the third cohort, they received prior TCR. Shunyakov said, “It’s pretty incredible to see that the response rate in patients who had prior exposure to T-cell–redirected therapy is about the same as in patients who are naive to TCR.”

Further, the median duration of response (DOR) was 9.5 months (95% CI, 6.7-13.4) in the first cohort, 17.5 months (95% CI, 12.5-25.1) in the second cohort, and 19.2 months (95% CI, 8.1-24.7) in the third cohort.

“If you look at the durability of response, that is where the significance of this product comes in,” said Dhakal. “If you look at the 0.8 mg/kg [subcutaneous] every other week, your median DOR is almost 18 months. That is quite impressive.”

He emphasized the similarity in DORs between the second cohort, which did not receive prior TCR, and the third cohort, which did. Shunyakov agreed that the positivity of these results, especially in the prior TCR cohort, was impressive. With these high and durable responses in this group of patients with an unmet need for new therapies, it is crucial to consider talquetamab for treatment, according to Dhakal.

Dhakal also pointed out that data from the benchmark studies from when CAR T-cell therapies were initially developed—the MAMMOTH and LocoMMotion (NCT04035226) studies—showed an overall survival (OS) of less than a year.

MonumenTAL-1 data significantly improved on that by showing prolonged survival in the same unexposed patient population and also in patients with prior exposure to T-cell–directed therapies.

The findings showed a median OS of 34.0 months (95% CI, 25.6-not estimable [NE]) in the first cohort, not reached (95% CI, NE-NE) in the second cohort, and 28.3 months (95% CI, 19.5-NE) in the third cohort. The respective 36-month OS rates were 49.3% (95% CI, 40.4%-57.6%), 60.8% (95% CI, 51.5%-68.8%), and 44.6% (95% CI, 31.4%-57.0%).

“In terms of overall survival, [these] data [are] unprecedented,” Shunyakov added.

In cohorts 1, 2, and 3, respectively, the median progression-free survival (PFS) was 7.5 months (95% CI, 5.7-9.4), 11.2 months (95% CI, 7.7-14.6), and 7.7 months (95% CI, 4.1-14.5).

Both clinicians also discussed the heavily pretreated patient population of the trial, as having 3 or more therapies was a requirement to enroll in phase 2; in the TCR-naive population, the median number of lines of therapy was 5, and in the TCR-exposed population, it was 6. Considering the positive data, even in this population, Shunyakov said it would be good to consider moving talquetamab up and treating patients with it as soon as possible. Dhakal highlighted that, as with most highly effective therapies, if you move them earlier, they will elicit better responses.

He also noted that, as patients require more lines of therapy, they are more likely to drop out of treatment, so waiting to administer it may be inadvertently preventing many patients from having the opportunity to receive this therapy.

The Dosing Schedule

With the trial broken down into 3 cohorts, several trends were noticeable. The first Shunyakov mentioned was how the weekly dosing schedule in the first cohort elicited higher responses, whereas the biweekly dosing schedule from cohort 2 demonstrated prolonged OS and PFS.

This likely means that biweekly dosing was better tolerated, and thus, patients can stay on treatment longer and continue to derive benefit. In his practice, Shunyakov has been administering talquetamab in the biweekly dosing schedule, almost from the beginning.

They do this because talquetamab can lead to mucositis, skin problems, and weight loss, which can become serious issues if they overadminister the drug.

Dhakal also uses the 0.8-mg/kg biweekly dosing schedule because it is convenient for the patient, and if the patient maintains their response, they may change to monthly dosing. According to him, no observable difference exists between the weekly and biweekly schedules regarding controlling the disease.

“There are no clinical predictors that will help you choose one dose vs another, but 0.8 mg/kg seems to be more friendly for the patient,” said Dhakal.

Shunyakov also stated that, in patients with prior exposure to BCMA, his next choice for therapy would be to target GPRC5D.

Updated Safety Profile

At the extended follow-up, the safety profile remained consistent with what was previously seen. Discontinuation rates due to adverse events (AEs) remained low, and no new discontinuations were observed due to GPRC5D-related AEs. However, a new safety signal, ataxia/balance disorders, was identified in association with talquetamab and had a low prevalence in MonumenTAL-1. The most common AEs of grades 3 and 4 were cytopenias, and there were no reported treatment-related deaths due to talquetamab.

Both doctors emphasized the infection-related AEs. Any-grade and grade 3/4 infections occurred in 61% and 23% of cohort 1, 71% and 21% of cohort 2, and 78% and 26% of cohort 3, respectively.

Although these rates are significant, Shunyakov compared them with the infection rates of BCMA-directed bispecific antibodies, which are close to 70% for any grade and 50% for grades 3/4. As he said, talquetamab is favorable. He attributed this to the mechanism of action of talquetamab because it primarily targets multiple myeloma cells rather than other plasma cells, which have very minimal or no effect on the healthy B lymphocytes. He added that he may even prefer talquetamab before a BCMA-
directed bispecific antibody due to the lower rate of infections.

For prophylaxis, although patients who receive BCMA-
directed bispecific antibodies almost always receive intravenous immunoglobulin replacement therapy, when patients who received talquetamab are several months into treatment, their immunoglobulin levels increase in most cases. In other words, most patients receiving talquetamab receive prophylaxis early on in treatment but may discontinue it later.

The new safety signal, ataxia/balance disorders, was also a point of conversation. Although neither doctor has seen it in practice yet, they have made it a point to tell their patients that it is a potential new toxicity that can be debilitating, even if it only occurs in less than 1% of patients.

Reference

Rasche L, Schinke CD, Touzeau C, et al. Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: analyses at an extended median follow-up. J Clin Oncol. 2025;43(suppl 16):7528. doi:10.1200/JCO.2025.43.16_suppl.7528

Story Continues

Muscat: The GCC nations made a GDP of USD 2.1431 trillion in 2023 – a 2.7% decrease from USD 2.2027 trillion in 2022, the GCC Statistical Center has announced.

The center showed that the available domestic product (the portion available for consumption and savings after taxes and other transfers) amounted to USD 1.9891 trillion, compared to USD 2.0515 trillion in 2022-a 3% decline.

It added that the total value added by the non-oil sector in the GCC countries at current prices by the end of 2023 was approximately USD 1.513 trillion, while the oil sector’s value added stood at USD 603.5 billion.

The data indicates that the non-oil sector’s contribution to the total GCC GDP at current prices rose to 71.5% by the end of 2023, compared to 65% by the end of 2022-reflecting an annual growth rate of 6.4%.

Mining and quarrying activities had the highest contribution to the GCC economy over the past five years, with an average of 28.3%, while manufacturing activities were the largest contributor within the non-oil sector, with an average of 11.7%.

Most economic activities recorded growth rates in 2023. The highest growth was seen in Financial and insurance activities (11.7%), Transport and storage (11.6%), Real estate activities (8.1%), Public administration and defense (7.9%), Wholesale and retail trade (7.6%) and Education (5.5%).

On the other hand, mining and quarrying activities and manufacturing industries saw a decline of 18.8% and 0.7%, respectively.

According to the data, the value of exports of goods and services by the end of 2023 reached USD 1.2587 trillion, contributing 59.5% to the GDP at current prices, with a 7.1% decrease compared to the previous year.

Final consumption expenditure-which includes total spending by households, non-profit institutions, and the government on goods and services for direct satisfaction of needs (not for further production)-amounted to USD 1.2456 trillion, marking an annual growth rate of 7.5%.

Gross capital formation (total investment in fixed capital and assets) reached USD 601.8 billion, with an annual growth rate of 5.5%.

Sanjeev Gupta is preparing a last-ditch attempt to save the remaining arm of his Liberty Steel business as government officials step up planning for a collapse of the business within days.

Gupta is understood to have spent the weekend planning an 11th hour rescue deal to save the company’s Speciality Steels UK (SSUK) division days before a courtroom showdown with its creditors on Wednesday.

The metals magnate hopes to secure a pre-pack administration deal that would allow the company to ditch its debts and other liabilities before being bought back by Gupta or parties connected to him.

The plan is likely to raise eyebrows in Whitehall where government officials are reportedly planning for a collapse of the heavily indebted steel division, while fraud investigations into other areas of Gupta’s business empire remain open.

A Liberty Steel spokesperson said discussions are ongoing to finalise options for SSUK that “best serve the interests of creditors, employees and the broader community”.

The restructuring specialist Begbies Traynor is working on the pre-pack deal, according to Sky News, which first reported the plans, but any deal would need Liberty Steel’s creditors, including the British tax authority HM Revenue and Customs (HMRC) and Swiss lender UBS, to agree to write off potentially hundreds of millions of pounds of debt.

Gupta has limited time to finalise any attempt to rescue his subsidiary before an expected court hearing on Wednesday relating to a winding-up petition, that was issued by a supplier over unpaid debts.

Government officials have reportedly stepped up planning for the collapse of SSUK if the winding-up petition is approved this week, according to Sky. The hearing, which has already been deferred several times, could force SSUK into compulsory liquidation, leaving a court-appointed official receiver to run the business.

SSUK is the UK’s third-largest steel producer and employs nearly 1,500 people. The South Yorkshire-based business includes an electric arc furnace at Rotherham, plus steelworks in Stocksbridge, near Sheffield, making steel for the car industry, as well as for use in construction and engineering.

Financial pressure has been mounting on Gupta’s metals and energy companies stretching from Australia through Singapore and Romania to northern England, known as the GFG Alliance.

The group has been in trouble since the 2021 failure of Greensill Capital, which collapsed after lending GFG about $5bn (£3.7bn). Gupta has been engaged in long-running talks with the administrators of Greensill, who are trying to recover the money.

GFG has been under investigation by the UK’s Serious Fraud Office since 2021 in relation to the Greensill financing. The company and Gupta have denied any wrongdoing.

Gupta is also being prosecuted by Companies House over the failure to file accounts for more than 70 UK businesses – including those of Liberty Pipes, based in Hartlepool. He has pleaded not guilty.

Some industry figures have said they expect the government to step in to ensure the plants keep running if they fall into liquidation – although it is not thought that the government will give financial support to Gupta’s companies.

A spokesperson at the Department for Business said: “We continue to closely monitor developments around Liberty Steel, including any public hearings, which are a matter for the company.”

Continued financial pressures on Gupta’s companies have followed years of difficulty for the wider UK steel industry. British steel production fell to its lowest level since the 1930s in 2024, and the government in effect took over the British Steel blast furnaces at Scunthorpe in April, amid fears of more than 2,700 job losses and the end of primary steel-making in the UK.

On Aug. 14, Bitcoin (BTC 0.18%) surged to a new all-time high above $124,000. The world’s most popular cryptocurrency is now up nearly 30% for the year and appears poised for further gains, based on improving market sentiment for crypto.

But can Bitcoin soar even higher, to $150,000? To answer that question, it’s important to consider what’s powering it.

Catalysts for Bitcoin

There are several different catalysts pushing Bitcoin higher right now. One of them, of course, is the recent executive order from the White House that will open the door for crypto to be included in 401(k) plans. This is expected to unlock trillions of dollars in new capital, a big chunk of which will likely flow into Bitcoin.

Another key factor is institutional adoption. Simply put, everyone seems to be buying Bitcoin these days. Corporations are buying Bitcoin. Bitcoin treasury companies are buying Bitcoin. And the U.S. government continues to suggest that it will find a “budget-neutral” way to buy Bitcoin. 

At the same time, money continues to flow into spot Bitcoin ETFs. This is arguably the best way to track institutional demand. If inflows into spot Bitcoin ETFs are positive, it means Bitcoin is likely to glide still higher. If inflows dry up, Bitcoin could be in for a rocky ride.

Finally, there’s the overall macroeconomic situation.​​ The broader market seems to be coming to grips with tariffs and what they likely will mean for the U.S. economy. For now, inflationary pressures do not seem as threatening as they were back in April, and investors are now expecting a series of interest rate cuts starting in September. Historically, lower rates have been favorable for crypto and have led to more money moving into risky, volatile assets such as Bitcoin.

So everything is trending in Bitcoin’s favor. A combination of institutional adoption, improving market sentiment, and expectations of rate cuts are juicing the market and helping to push Bitcoin higher.

What do prediction markets think?

That said, Bitcoin is hardly a lock to hit $150,000 this year. One way to get a sense of what the overall market thinks is by looking at data from prediction markets. There, people are trading contracts based on where they think the price of Bitcoin is going next.

On the Kalshi prediction market, for example, traders think Bitcoin has a 75% chance of hitting $130,000 this year, a 53% chance of hitting $140,000, and a 37% chance of hitting $150,000. So, basically, there’s a 1-in-3 chance that Bitcoin will hit $150,000 by the end of the year.

Things get a bit dicier from there. For example, there is only a 27% chance that Bitcoin will hit $160,000 and a 10% chance that Bitcoin will hit $200,000. This last data point is particularly noteworthy because, at the start of the year, just about everyone was predicting that Bitcoin would double in value and easily hit $200,000.

What to look for next

The market is pricing in an interest rate cut, but that can’t happen if inflation rears its ugly head. And that’s exactly what happened almost as soon as Bitcoin hit $124,000. New economic data suggested that inflationary pressures were building. As a result, Bitcoin quickly slid back down to $120,000.

With that in mind, Bitcoin investors should keep a close eye on any and all economic data that the Federal Reserve might take into account when deciding how to adjust interest rates in September. Notably, this marks a departure from the way people invested in Bitcoin in the past. Historically, money has flowed into Bitcoin regardless of what people think the Fed might (or might not) be doing.

Just a few years ago, Bitcoin was completely uncorrelated with any major asset class. And that meant Bitcoin could zig when other assets zagged. But we’re starting to see a correlation with stocks, and especially tech stocks. With institutional investors lining up for a piece of Bitcoin, the world’s most popular cryptocurrency is starting to behave more and more like a risky, high-upside tech stock.

Long-term, I’m still bullish on Bitcoin. But as we saw back in April, when Bitcoin buckled under the threat of tariffs, it remains a highly volatile digital asset subject to the broader macroeconomic outlook. There’s a reasonably good chance Bitcoin will hit $150,000, but only if the broader economy doesn’t deteriorate.

Children who may have been subjected to unnecessary hip dysplasia surgery must wait until next year before they are assessed by a team of external experts for a second medical opinion.

In May, the HSE published an independent audit on hip surgery thresholds for children with developmental dysplasia of the hip.

It examined 147 cases across three hospitals: Temple Street, the National Orthopaedic Hospital Cappagh and Crumlin Hospital. In Temple Street, 60 per cent of surgeries audited did not meet the clinical threshold for surgical intervention, while this was the case for 79 per cent in the Cappagh hospital.

Following the report, the HSE announced it was commissioning an independent expert review panel that will work to review patient files to determine the appropriateness of the original decision to operate.

The HSE said then that the review panel would be set up within six months. However, a spokeswoman for the executive has now said it will be January before the review of individual cases begins.

The health service issued an international call for experts, with applications accepted up until last Friday.

“Expressions of interest have been received from a wide range of regions including Ireland, the UK, the USA, Canada, Asia and other parts of Europe,” the spokeswoman said.

“These submissions will be subject to a shortlisting and recruitment process prior to the formal announcement of the panel, which is expected to convene in September.”

She said an international expert has been identified and agreed to chair the external panel, and terms are being negotiated.

The organisation is designing a “robust scientific and methodological framework” for the review, which is expected to be agreed between September and December this year.

“It is expected that the review of individual cases will commence in January. This timeline reflects the complexity of the work involved and the need to ensure a rigorous and comprehensive approach,” it added.

The HSE, Children’s Health Ireland (CHI) and patient advocates held a meeting on the external review panel last Thursday.

In a statement following the meeting, Hip Dysplasia Advocacy Group, a newly-established representative organisation, said there must be “full transparency” between the HSE and the families regarding these reviews. It said “everyone is left completely in the dark”.

“We strongly suggested they set up a webpage to inform families of updates in a timely manner and we hope to see this implemented swiftly,” the statement said.

The advocacy group described the engagement with CHI at the meeting as positive, adding that the paediatric healthcare provider anticipates all follow-up appointments for affected children will be completed by the end of the year.

Sponsored by Blue Buffalo Company

A professor of nutrition at the University of Minnesota College of Veterinary Medicine in St Paul, Julie Churchill, DVM, PhD, DACVIM (Nutrition), teaches veterinary students at all stages, from first year to final rotations. “I have the luckiest job in the world,” she said. “I have the perfect mix of about 50% of my time is in the classroom and approximately 50% of my time is in the clinic. So I get to see patients, I get to work with clients, and I get to work with house officers in the clinical settings, so residents and interns as well as colleagues.”

As a specialist in nutrition, Churchill does work that extends well beyond healthy food and preparing diet plans. It includes comorbidities and complex cases that do not always have a clearly identifiable dietary plan to help manage conditions. Her patients range from puppies and kittens to older animals. “I see such a variety [of patient cases], so it is never a dull moment,” Churchill said. “We do a nutrition assessment for every patient in [the] ICU [intensive care unit], so I have a great passion for critical care and our hospitalized patients. And I get to work with our primary care [team], so I get to see healthy [pets] too.”

Churchill is a volunteer for the Association for Pet Obesity Prevention and works with the organization to find ways to help health care teams prevent and treat obesity and educate pet owners about weight management. She was also invited by the American Animal Hospital Association to participate in a task force addressing the organization’s weight management guidelines.

“The goal was how can we develop tools to make weight management easier for the health care team….Nutrition is a team sport,” Churchill said.

She urged veterinary professionals to not shy away from conversations about obesity. “Pet parents are craving these conversations. Veterinarians and veterinary teams are still the most trusted source,” she said. “We not only care for the pets throughout life, but we build this lovely, loyal clientele. We build clients for life by having those conversations and being there for their pet at every stage of life.”

The 2025 class of dvm360 Veterinary Heroes will be honored at a celebratory luncheon at the Fetch dvm360 Conference in Kansas City, Missouri. Click here to learn more or register for the event.